Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

4,052 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
A Phase II Study to Compare the Safety and Efficacy of Direct Oral Anticoagulants versus Subcutaneous Dalteparin for Cancer-Associated Venous Thromboembolism in Patients with Advanced Upper Gastrointestinal, Hepatobiliary and Pancreatic Cancer: PRIORITY.
Kim JH, Yoo C, Seo S, Jeong JH, Ryoo BY, Kim KP, Lee JB, Lee KW, Kim JW, Kim IH, Kang M, Ryu H, Cheon J, Park SR. Kim JH, et al. Among authors: lee jb, lee kw. Cancers (Basel). 2022 Jan 22;14(3):559. doi: 10.3390/cancers14030559. Cancers (Basel). 2022. PMID: 35158827 Free PMC article.
Epidermal growth factor receptor intron 1 CA dinucleotide repeat polymorphism and survival of advanced gastric cancer patients treated with cetuximab plus modified FOLFOX6.
Han SW, Oh DY, Im SA, Park SR, Lee KW, Song HS, Lee NS, Lee KH, Choi IS, Lee MH, Kim MA, Kim WH, Bang YJ, Kim TY. Han SW, et al. Among authors: lee ns, lee mh, lee kh, lee kw. Cancer Sci. 2010 Mar;101(3):793-9. doi: 10.1111/j.1349-7006.2009.01447.x. Epub 2009 Nov 23. Cancer Sci. 2010. PMID: 20047592 Free PMC article. Clinical Trial.
Multicenter phase II study of second-line bevacizumab plus doublet combination chemotherapy in patients with metastatic colorectal cancer progressed after upfront bevacizumab plus doublet combination chemotherapy.
Hong YS, Lee J, Kim KP, Lee JL, Park YS, Park JO, Park SH, Kim SY, Baek JY, Kim JH, Lee KW, Kim TY, Kim TW. Hong YS, et al. Among authors: lee j, lee kw, lee jl. Invest New Drugs. 2013 Feb;31(1):183-91. doi: 10.1007/s10637-012-9853-3. Epub 2012 Jul 11. Invest New Drugs. 2013. PMID: 22782485 Clinical Trial.
S-1 plus oxaliplatin versus capecitabine plus oxaliplatin for first-line treatment of patients with metastatic colorectal cancer: a randomised, non-inferiority phase 3 trial.
Hong YS, Park YS, Lim HY, Lee J, Kim TW, Kim KP, Kim SY, Baek JY, Kim JH, Lee KW, Chung IJ, Cho SH, Lee KH, Shin SJ, Kang HJ, Shin DB, Jo SJ, Lee JW. Hong YS, et al. Among authors: lee j, lee kh, lee jw, lee kw. Lancet Oncol. 2012 Nov;13(11):1125-32. doi: 10.1016/S1470-2045(12)70363-7. Epub 2012 Oct 10. Lancet Oncol. 2012. PMID: 23062232 Clinical Trial.
S-1 plus oxaliplatin versus capecitabine plus oxaliplatin for the first-line treatment of patients with metastatic colorectal cancer: updated results from a phase 3 trial.
Kim ST, Hong YS, Lim HY, Lee J, Kim TW, Kim KP, Kim SY, Baek JY, Kim JH, Lee KW, Chung IJ, Cho SH, Lee KH, Shin SJ, Kang HJ, Shin DB, Lee JW, Jo SJ, Park YS. Kim ST, et al. Among authors: lee j, lee kh, lee jw, lee kw. BMC Cancer. 2014 Nov 26;14:883. doi: 10.1186/1471-2407-14-883. BMC Cancer. 2014. PMID: 25424120 Free PMC article. Clinical Trial.
4,052 results